Psoralen-loaded polymeric lipid nanoparticles combined with paclitaxel for the treatment of triple-negative breast cancer

被引：8

作者：

Liu, Fengjie ^{[1
]}

Li, Lihong ^{[1
]}

Lan, Meng ^{[1
]}

Zou, Tengteng ^{[1
]}

Kong, Zhaodi ^{[1
]}

Cai, Tiange ^{[2
]}

Wu, Xiaoyu ^{[3
]}

Cai, Yu ^{[1
,4
]}

机构：

[1] Jinan Univ, Coll Pharm, Guangzhou 510632, Guangdong, Peoples R China

[2] Liaoning Univ, Coll Life Sci, Shenyang 110036, Peoples R China

[3] Univ Toronto, Leslie Dan Fac Pharm, Adv Pharmaceut & Drug Delivery Lab, 144 Coll St, Toronto, ON, Canada

[4] Jinan Univ, Guangdong Key Lab Tradit Chinese Med Informat Tec, Guangzhou 510632, Peoples R China

来源：

NANOMEDICINE | 2021年 / 16卷 / 27期

关键词：

breast cancer; metastasis; paclitaxel; polymeric lipid nanoparticle; psoralen; NF-KAPPA-B; MULTIDRUG-RESISTANCE; HYBRID NANOPARTICLES; NEOADJUVANT CHEMOTHERAPY; TUMOR-MICROENVIRONMENT; INDUCED APOPTOSIS; EFFICACY; DOXORUBICIN; METASTASIS; PHARMACOKINETICS;

D O I：

10.2217/nnm-2021-0241

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Background: Chemotherapeutic drugs are associated with toxic effects. Metastasis is the leading cause of death in breast cancer patients. Aim: To evaluate the antitumor effect of paclitaxel (PTX) combined with psoralen-loaded polymeric lipid nanoparticles (PSO-PLNs) in triple-negative breast cancer. Methods: After treatment of samples, cell viability, apoptosis, migration, invasion, expression of proteins in the IRAK1/NF-kappa B/FAK signal pathway, biodistribution and pathological characteristics were detected. Results: Compared with the control group, the PTX + PSO-PLNs group showed increased apoptosis and reduced migration, invasion and expression of phosphorylated IRAK1 and NF-kappa B, with significant inhibition of tumor growth and lung metastases and no obvious toxicity. Conclusion: Combined administration of PTX and PSO-PLNs exerted a synergistic effect and significantly inhibited the growth and metastasis of triple-negative breast cancer.

引用

页码：2411 / 2430

页数：20

共 50 条

[21] Imaging of triple-negative breast cancer
Dogan, B. E.
Turnbull, L. W.
ANNALS OF ONCOLOGY, 2012, 23 : 23 - 29
[22] Exploring paclitaxel-loaded adenosine-conjugated PEGylated PLGA nanoparticles for targeting triple-negative breast cancer
Dasharath Chaudhari
Kaushik Kuche
Vivek Yadav
Rohan Ghadi
Tushar Date
Nallamothu Bhargavi
Sanyog Jain
Drug Delivery and Translational Research, 2023, 13 : 1074 - 1087
[23] Exploring paclitaxel-loaded adenosine-conjugated PEGylated PLGA nanoparticles for targeting triple-negative breast cancer
Chaudhari, Dasharath
Kuche, Kaushik
Yadav, Vivek
Ghadi, Rohan
Date, Tushar
Bhargavi, Nallamothu
Jain, Sanyog
DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2023, 13 (04) : 1074 - 1087
[24] Metastatic Triple-negative Breast Cancer
Rakha, E. A.
Chan, S.
CLINICAL ONCOLOGY, 2011, 23 (09) : 587 - 600
[25] Methylseleninic Acid Enhances Paclitaxel Efficacy for the Treatment of Triple-Negative Breast Cancer
Qi, Yanfeng
Fu, Xueqi
Xiong, Zhenggang
Zhang, Haitao
Hill, Steven M.
Rowan, Brian G.
Dong, Yan
PLOS ONE, 2012, 7 (02):
[26] A Paclitaxel Prodrug with Copper Depletion for Combined Therapy toward Triple-Negative Breast Cancer
Hao, Dengyuan
Meng, Qian
Li, Chaonan
Lu, Shaojin
Xiang, Xiujuan
Pei, Qing
Jing, Xiabin
Xie, Zhigang
ACS NANO, 2023, : 12383 - 12393
[27] Triple-negative breast cancer: new treatment strategies
Krawczyk, Natalia
Banys-Paluchowski, Maggie
Fehm, Tanja
GYNAKOLOGE, 2020, 53 (11): : 771 - 779
[28] Advances in the systemic treatment of triple-negative breast cancer
Lebert, J. M.
Lester, R.
Powell, E.
Seal, M.
McCarthy, J.
CURRENT ONCOLOGY, 2018, 25 : S142 - S150
[29] Current approaches in treatment of triple-negative breast cancer
Wahba, Hanan Ahmed
El-Hadaad, Hend Ahmed
CANCER BIOLOGY & MEDICINE, 2015, 12 (02) : 106 - 116
[30] Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer
Takai, Ken
Le, Annie
Weaver, Valerie M.
Werb, Zena
ONCOTARGET, 2016, 7 (50) : 82889 - 82901

← 1 2 3 4 5 →